Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06615557 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | PHASE3 | ACTIVE NOT_RECRUITING | 238 | — | — | Sep 16, 2024 | Apr 1, 2027 | May 22, 2026 | 26 | United States |
The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt).
| Arm | Type | Description |
|---|---|---|
| Fasedienol Nasal Spray | EXPERIMENTAL | - |
| Placebo Nasal Spray | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fasedienol Nasal Spray | DRUG | Nasal spray delivered 20 minutes before the PSC |
| Placebo Nasal Spray | DRUG | Nasal spray delivered 20 minutes before the PSC |
Inclusion Criteria: * Written informed consent provided prior to conducting any study-specific assessment. * Male and female adults, 18 through 65 years of age, inclusive. * Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirmed ...